Disorders Due to Use of Volatile Inhalants (ICD-11: 6C4B)

1. Introduction

Disorders due to the use of volatile inhalants represent a significant clinical challenge, especially among young and vulnerable populations. These disorders involve the use of chemical substances that are in gaseous or vapor phase at room temperature, including organic solvents, glues, gasoline, nitrites, and gases such as nitrous oxide, trichloroethane, butane, toluene, fluorocarbons, ether, and halothane.

The clinical importance of these disorders lies in the fact that volatile inhalants are frequently the first psychoactive substance used by adolescents and children, due to their wide availability, low cost, and ease of access. Unlike other controlled substances, many inhalants are legal domestic or industrial products, making their control particularly challenging.

The impact on public health is considerable, as inhalant use can cause severe and irreversible neurological damage, including cognitive impairment, dementia, liver and kidney injuries, in addition to acute cardiac risks that can result in sudden death, even in novice users. Correct coding of these disorders in ICD-11 is critical for adequate epidemiological monitoring, planning of preventive interventions, appropriate allocation of therapeutic resources, and development of effective public policies. Accurate classification also facilitates communication among health professionals, allows for international comparative studies, and ensures that patients receive treatment appropriate to their specific needs.

2. Correct ICD-11 Code

Code: 6C4B

Description: Disorders due to use of volatile inhalants

Parent category: Disorders due to substance use

Official definition: Disorders due to use of volatile inhalants are characterized by the pattern and consequences of use of these substances. Volatile inhalants include a variety of compounds that are in the gaseous or vapor phase at room temperature, encompassing various organic solvents, glues, gasoline, nitrites, and gases such as nitrous oxide, trichloroethane, butane, toluene, fluorocarbons, ether, and halothane.

These substances present a range of pharmacological properties, but are predominantly central nervous system depressants, and many also have vasoactive effects. They tend to be used by younger people and may be used when access to other psychoactive substances is difficult or impossible. Intoxication by volatile inhalant is well recognized clinically. Volatile inhalants possess dependence-producing properties; dependence and withdrawal from volatile inhalants are recognized, although relatively uncommon globally. Mental disorders induced by volatile inhalants are described, which may also cause significant neurocognitive impairment, including dementia-like presentations.

This code is part of the ICD-11 classification system, which offers greater specificity and diagnostic clarity compared to previous versions, allowing better epidemiological tracking and therapeutic planning.

3. When to Use This Code

The code 6C4B should be used in specific clinical situations where there is clear evidence of a disorder related to the use of volatile inhalants. Below are detailed practical scenarios:

Scenario 1: Adolescent with Regular Glue Use Pattern A 14-year-old patient is brought for evaluation after being found repeatedly inhaling shoe glue. The evaluation reveals that use has occurred for at least six months, with increasing frequency, impairment in school performance, social isolation, and episodes of intoxication characterized by euphoria, disinhibition, and perceptual alterations. The patient reports difficulty controlling use and continues the practice despite knowing the risks. This case meets the criteria for a disorder due to the use of volatile inhalants.

Scenario 2: Acute Intoxication from Solvent Inhalation A young patient presents to the emergency department with acute confusional state, nystagmus, ataxia, slurred speech, and characteristic solvent odor. The history obtained from companions reveals recent inhalation of thinner. This episode of acute intoxication from volatile inhalant should be coded with 6C4B, specifying the intoxication pattern.

Scenario 3: Nitrous Oxide Dependence A young adult seeks treatment reporting compulsive use of nitrous oxide ("laughing gas") for two years. The patient describes a need for increasing amounts to obtain the desired effect (tolerance), symptoms of discomfort when attempting to stop (withdrawal), and continued use despite neurological symptoms such as tingling in the extremities. This presentation of dependence justifies the use of code 6C4B.

Scenario 4: Mental Disorder Induced by Inhalants A patient with a history of chronic toluene use develops persistent psychotic symptoms, including visual hallucinations and paranoid delusions, directly related to substance use. Neuropsychological evaluation reveals cognitive deficits consistent with prolonged exposure to inhalants. This case requires code 6C4B with specification of the induced mental disorder.

Scenario 5: Harmful Use with Medical Consequences An adolescent presents with recurrent episodes of cardiac arrhythmia and documented liver injury, with a history of intermittent but frequent gasoline inhalation use. Even without complete criteria for dependence, the pattern of harmful use with serious medical consequences justifies coding 6C4B.

Scenario 6: Neurocognitive Impairment Induced by Inhalants A patient with a history of prolonged use of multiple solvents presents with progressive cognitive decline, with deficits in memory, executive function, and processing speed, characterizing dementia induced by volatile inhalants. This severe presentation requires code 6C4B with specification of neurocognitive impairment.

4. When NOT to Use This Code

It is essential to distinguish situations where code 6C4B is not appropriate to avoid classification errors:

Occupational Exposure without Disorder: Workers exposed to solvents or other inhalants in the workplace, without a pattern of intentional use to obtain psychoactive effects, should not receive this code. In these cases, codes related to occupational intoxications or adverse effects of chemical substances should be used.

Use of Other Psychoactive Substances: If the patient presents a disorder related to the use of alcohol, cannabis, opioids, stimulants, or other substances that are not volatile inhalants, specific codes for these substances should be used (6C40 for alcohol, 6C41 for cannabis, etc.).

Single Accidental Intoxication: An isolated accidental exposure to chemical vapors, without a pattern of intentional use or consequences that characterize a disorder, does not justify code 6C4B. Codes for accidental intoxication should be used.

Primary Psychiatric Disorders: Patients with schizophrenia, bipolar disorder, or other primary mental disorders that are not induced by inhalants should receive specific codes for these conditions, even if they make occasional use of inhalants.

Medicinal Use of Inhalational Anesthetics: The controlled administration of inhalational anesthetics (such as nitrous oxide or halothane) in appropriate medical context does not constitute a disorder due to inhalant use and should not be coded with 6C4B.

Multiple Chemical Sensitivity Syndrome: Patients who report symptoms following exposure to multiple environmental chemical substances, without a pattern of intentional inhalant use, require differentiated evaluation and other diagnostic codes.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

Confirmation of the diagnosis of disorder due to use of volatile inhalants requires comprehensive clinical evaluation. The professional should conduct a detailed interview investigating the pattern of use, including specific type of inhalant, frequency, duration, context of use, and motivations. It is essential to assess the presence of loss of control over use, tolerance (need for increasing amounts), withdrawal symptoms, and continued use despite negative consequences.

The evaluation should include complete physical examination, seeking signs of acute intoxication (nystagmus, ataxia, slurred speech, characteristic odor) and chronic consequences (perioral lesions in glue users, neurological deficits, signs of hepatopathy or nephropathy). Standardized screening instruments for substance use may be useful, although few are specific for inhalants.

Formal neuropsychological evaluation is recommended in cases of chronic use to document cognitive impairment. Laboratory tests may include liver function, renal function, complete blood count, and when indicated, neuroimaging to assess structural brain changes.

Step 2: Verify Specifiers

After confirming the primary diagnosis, it is necessary to specify additional characteristics. ICD-11 allows specification of different disorder patterns:

Single episode of harmful use: Use that caused damage to physical or mental health, but there is no repeated pattern.

Pattern of harmful use: Repeated use causing damage to physical or mental health.

Dependence: Presence of impaired control over use, priority given to use over other activities, and continuation despite negative consequences. May include physiological features such as tolerance and withdrawal.

Intoxication: Transient state following administration of the inhalant, with alterations in consciousness, cognition, perception, affect, or behavior.

Withdrawal: Set of symptoms that occur after cessation or reduction of prolonged use.

Induced mental disorders: Including psychotic, mood, or anxiety disorders directly caused by inhalant use.

Neurocognitive impairment: From mild deficits to inhalant-induced dementia.

Step 3: Differentiate from Other Codes

6C40 - Disorders due to use of alcohol: The fundamental difference lies in the substance used. While 6C4B refers specifically to volatile inhalants (solvents, glues, gases), 6C40 is exclusive to alcoholic beverages. The clinical presentation may be similar in acute intoxication, but the patterns of use, affected populations, and long-term consequences differ significantly.

6C41 - Disorders due to use of cannabis: This code is specific for use of natural cannabis. The distinction is clear by substance: volatile inhalants versus cannabis. The psychoactive effects, health risks, and user profiles are distinct, although there may be concurrent use of multiple substances.

6C42 - Disorders due to use of synthetic cannabinoids: Differs from 6C4B by the chemical class of the substance. Synthetic cannabinoids are compounds designed to mimic effects of cannabis, while volatile inhalants are industrial or household chemicals with central nervous system depressant properties.

Proper differentiation requires detailed history about which specific substance is being used. In cases of multiple substance use, multiple codes may be necessary.

Step 4: Required Documentation

Proper documentation is essential to justify coding and ensure continuity of care. The clinical record should include:

Checklist of Mandatory Information:

Specific type of inhalant used (glue, solvent, gasoline, nitrous oxide, etc.)
Pattern of use: frequency, amount, total duration of use
Route of administration (direct inhalation, use of plastic bag, etc.)
Age of onset of use
Context of use (individual, group, recreational, etc.)
Symptoms of intoxication observed or reported
Presence or absence of tolerance and withdrawal
Physical, psychological, and social consequences of use
Previous cessation attempts and outcomes
Medical and psychiatric comorbidities
Concurrent use of other substances
Results of physical, laboratory, and neuropsychological examinations
Risk assessment (including risk of sudden death)
Proposed therapeutic plan

The record should be clear, objective, and based on documented clinical evidence, avoiding personal judgments and maintaining professional language.

6. Complete Practical Example

Clinical Case

Initial Presentation: A 15-year-old adolescent is brought to the mental health service by his guardians, who are concerned about behavioral changes over the past eight months. They report that the young man has become progressively isolated, abandoned activities he previously enjoyed, shows declining school performance, and has been found several times with empty aerosol cans in his room. Recently, the guardians noticed episodes in which the adolescent displayed strange behavior, slurred speech, and characteristic chemical odor.

Evaluation Performed: During the clinical interview, initially resistant, the patient eventually admits to regular use of aerosol deodorant by inhalation, initiated approximately 10 months ago after experimentation with peers. Use began as an occasional recreational activity on weekends, but progressively increased to almost daily use, frequently alone in his room. The patient reports that initially one or two inhalations were sufficient to obtain euphoria and relaxation, but currently requires prolonged sessions with multiple inhalations.

He describes symptoms during intoxication including initial euphoria, sensation of lightness, mild visual distortions, disinhibition and relaxation, followed by drowsiness. He acknowledges experiencing headache, nausea, and irritability on days when he attempted to stop use. The patient admits that use interferes with his school activities and relationships, but feels difficulty controlling the urge to use, especially when stressed or bored.

Physical examination reveals discrete perioral lesions compatible with repeated exposure to chemical substances. Neurological examination shows mild fine tremor of extremities, but without other focal deficits. Brief cognitive assessment suggests possible impairment of attention and working memory. Laboratory tests show liver and kidney function within normal limits, but the complete blood count reveals mild anemia.

Diagnostic Reasoning: The case presents clear elements of disorder due to use of volatile inhalants. The pattern of use evolved from experimental to regular and frequent, with progressive loss of control. The presence of tolerance is evidenced by the need for increasing amounts to obtain the desired effect. There are symptoms suggestive of withdrawal (headache, irritability) when use is discontinued. Use continues despite clear negative consequences (academic impairment, social isolation, physical changes). The patient recognizes difficulty controlling use, a central characteristic of dependence.

The substance used (aerosol containing propellants and other volatile compounds) clearly falls within the category of volatile inhalants. There is no evidence of problematic use of other psychoactive substances. Symptoms are not better explained by another primary mental disorder, although monitoring for comorbidities is necessary.

Coding Justification: This case meets criteria for dependence on volatile inhalants, characterized by a pattern of compulsive use, loss of control, tolerance, withdrawal symptoms, and continuation despite negative consequences. Chronic and regular use, with significant impact on functioning, justifies the diagnosis of disorder due to use of volatile inhalants.

Step-by-Step Coding

Criteria Analysis:

Substance: Volatile inhalant (aerosol) ✓
Pattern of problematic use: Regular and progressive ✓
Loss of control: Difficulty stopping or reducing ✓
Tolerance: Need for increasing amounts ✓
Withdrawal: Symptoms when attempting to stop ✓
Negative consequences: Academic and social impairment ✓
Duration: More than 8-10 months ✓

Code Selected: 6C4B - Disorders due to use of volatile inhalants

Specification: Dependence on volatile inhalants

Complete Justification: Code 6C4B is appropriate because the patient presents a disorder specifically related to use of volatile inhalants (aerosol), with a pattern that meets criteria for dependence. The substance used does not fall into other categories (alcohol, cannabis, opioids, etc.), being clearly a volatile inhalant. The pattern of use evolved from experimental to dependent, with multiple indicators of severity including tolerance, withdrawal, loss of control, and continuation despite consequences.

Applicable Complementary Codes:

Code for perioral lesions related to use
Code for possible mild neurocognitive disorder induced by inhalants (if confirmed on formal neuropsychological evaluation)
Codes for identified associated medical conditions (anemia)

7. Related Codes and Differentiation

Within the Same Category

6C40: Disorders due to use of alcohol

When to use 6C40: This code should be used when the disorder is specifically related to consumption of alcoholic beverages (beer, wine, spirits). Ethyl alcohol is the substance involved, with patterns of use that may include acute intoxication, harmful use, dependence, and substance-induced mental disorders.

Main difference vs. 6C4B: The fundamental distinction lies in the substance. While 6C40 refers exclusively to ethyl alcohol consumed as a beverage, 6C4B encompasses volatile inhalants (solvents, glues, gases). The affected populations also differ: alcohol use is more prevalent in adults and socially accepted in many cultures, while inhalants are more common among adolescents and vulnerable populations. Long-term medical consequences also differ, with alcohol primarily causing hepatic disease, pancreatitis, and severe dependence, while inhalants more frequently cause irreversible neurological damage.

6C41: Disorders due to use of cannabis

When to use 6C41: Applies when the disorder involves use of natural cannabis (marijuana, hashish), derived from the Cannabis sativa plant. Includes patterns of intoxication, harmful use, dependence, and cannabis-induced mental disorders.

Main difference vs. 6C4B: The essential difference lies in the substance class and mechanism of action. Cannabis acts primarily through endogenous cannabinoid receptors, producing characteristic effects such as euphoria, perceptual alterations, increased appetite, and relaxation. Volatile inhalants are central nervous system depressants with multiple mechanisms of action. Cannabis generally does not cause severe organic damage comparable to inhalants, which can produce irreversible neurological, hepatic, and renal lesions. The safety profile and acute risks also differ significantly.

6C42: Disorders due to use of synthetic cannabinoids

When to use 6C42: This code is specific for disorders related to use of synthetic cannabinoids, artificial chemical substances designed to mimic cannabis effects but with different molecular structure. Frequently marketed as "incense" or "aromatic herbs".

Main difference vs. 6C4B: Although both involve synthetic chemical substances, synthetic cannabinoids are specifically designed to activate cannabinoid receptors, while volatile inhalants are industrial or household products with nonspecific depressant properties of the central nervous system. Synthetic cannabinoids are generally smoked or vaporized, while inhalants are inhaled directly. Toxicity profiles and risks also differ, with synthetic cannabinoids more frequently causing acute psychosis and seizures, while inhalants more commonly cause fatal cardiac arrhythmias and chronic neurological damage.

Differential Diagnoses

Primary Psychotic Disorders: Patients with schizophrenia or other psychotic disorders may present with symptoms similar to those induced by inhalants, but the temporal history and relationship to substance use are fundamental for differentiation. In inhalant-induced psychotic disorders, symptoms emerge during or shortly after use and generally improve with abstinence.

Neurocognitive Disorders of Other Etiologies: Dementias caused by Alzheimer's disease, vascular lesions, or other medical conditions should be differentiated from inhalant-induced dementia through detailed history of substance use, pattern of cognitive deficits, and neuroimaging.

Intoxication by Other Substances: Acute intoxication by alcohol, sedatives, or other depressant substances may mimic inhalant intoxication. Characteristic odor, history of use, and toxicological detection aid in differentiation.

Primary Anxiety or Mood Disorders: Anxious or depressive symptoms may occur both as primary disorders and as inhalant-induced. The chronology of symptoms in relation to substance use is crucial for differentiation.

8. Differences with ICD-10

In ICD-10, disorders related to the use of volatile inhalants were coded within category F18 (Mental and behavioral disorders due to use of volatile solvents). This category included subdivisions such as F18.0 (acute intoxication), F18.1 (harmful use), F18.2 (dependence syndrome), among others.

Main changes in ICD-11:

ICD-11 introduces a more integrated and flexible structure with code 6C4B. The main conceptual change is the dimensional approach that allows specification of multiple characteristics simultaneously, instead of the rigid subcategory structure of ICD-10. In ICD-11, one can code a single disorder with multiple specifiers (for example, dependence with current intoxication and associated cognitive impairment).

The terminology was updated, with "disorders due to use" replacing "mental and behavioral disorders due to use," reflecting a broader understanding that includes physical and social consequences in addition to mental ones. ICD-11 also offers greater clarity in the definition of dependence, emphasizing impaired control over use as a central feature, rather than focusing exclusively on physiological aspects such as tolerance and withdrawal.

Practical impact:

These changes facilitate more precise and clinically relevant coding, allowing capture of the complexity of disorders related to inhalant use. Professionals can document multiple characteristics of the disorder simultaneously without the need for multiple codes. The more flexible structure also facilitates research and international comparisons, improving the epidemiological understanding of these disorders. For health systems, the transition requires training of professionals and updating of information systems, but results in more accurate data for planning and evaluation of services.

9. Frequently Asked Questions

How is the diagnosis of volatile inhalant use disorder made?

The diagnosis is fundamentally clinical, based on a detailed interview with the patient and, when possible, collateral informants. The professional investigates the substance use pattern, including the specific type of inhalant, frequency, duration, and context. The presence of loss of control, tolerance, withdrawal symptoms, and continued use despite negative consequences is assessed. The physical examination seeks signs of acute intoxication or chronic use, such as perioral lesions, neurological deficits, or characteristic odor. There are no specific laboratory tests for diagnosis, but tests can identify consequences of use, such as hepatic, renal, or hematological alterations. Neuropsychological evaluation can document cognitive impairment. The temporal history is crucial: symptoms must be clearly related to inhalant use and not be better explained by other medical or psychiatric conditions.

Is treatment available in public health systems?

The availability of treatment varies significantly among different regions and health systems. Many public health systems offer services for substance use disorders, including inhalants, through specialized chemical dependency centers, community mental health services, or integrated programs. Treatment is generally multidisciplinary, involving physicians, psychologists, social workers, and other professionals. Interventions include detoxification when necessary, psychotherapy (especially cognitive-behavioral approaches and motivational interviewing), family support, psychosocial rehabilitation, and treatment of comorbidities. However, access may be limited in some areas, especially in regions with scarce resources or where inhalant use is not recognized as a public health priority. Non-governmental organizations and mutual support groups can also complement public services.

How long does treatment last?

The duration of treatment varies considerably depending on the severity of the disorder, presence of comorbidities, individual response to treatment, and available social support. Cases of harmful use or isolated episodes may respond to brief interventions lasting from a few weeks to a few months. Dependence disorders generally require more prolonged treatment, often lasting several months to years. The initial intensive phase may last three to six months, followed by maintenance follow-up and relapse prevention for an extended period. It is important to understand that dependence treatment is often a long-term process, with possible relapses that require therapeutic adjustments. Treatment should not be viewed as linear, but as a continuous recovery process. Some patients may require intermittent or continuous support for years. The ideal approach is individualized, adapted to the specific needs of each patient.

Can this code be used on medical certificates?

The use of diagnostic codes on medical certificates must follow ethical principles and local regulations. In many jurisdictions, medical certificates to justify absences from work or school generally do not include the specific diagnostic code, but only describe the need for leave for health reasons, preserving patient confidentiality. When codes are necessary for administrative or insurance purposes, code 6C4B can be used, but always respecting patient consent and privacy regulations. It is essential that health professionals be aware of the social and legal implications of documenting substance use disorders, considering possible stigma, discrimination, or legal consequences. In contexts where diagnostic documentation is necessary for access to treatment or benefits, appropriate use of the code is important to ensure that the patient receives adequate care.

Do volatile inhalants cause physical dependence like other drugs?

Yes, volatile inhalants can cause both psychological and physical dependence, although physical dependence is less common compared to substances such as alcohol or opioids. Psychological dependence, characterized by a strong desire to use, difficulty controlling use, and continued use despite negative consequences, is more frequent. Tolerance can develop, requiring increasing amounts to obtain the desired effect. Withdrawal syndrome has been documented, although it is relatively uncommon and generally less severe than withdrawal from alcohol or benzodiazepines. Withdrawal symptoms may include anxiety, irritability, tremors, nausea, sweating, and insomnia. The risk of dependence varies among different types of inhalants and use patterns. Chronic and intense use increases the risk of developing dependence. It is important not to underestimate the addictive potential of these substances, especially considering that easy access and misconceptions about safety can facilitate repeated use and progression to problematic patterns.

What are the most serious risks of inhalant use?

Volatile inhalants present serious and unique risks. The most feared risk is "sudden death from inhalation," which can occur even on the first use. This phenomenon results from fatal cardiac arrhythmia, often triggered by sensitization of the myocardium to catecholamines, especially when the user is startled or engages in physical activity during or shortly after inhalation. Other acute risks include asphyxia (when inhalants are used in plastic bags), trauma from falls during intoxication, and aspiration of vomit. Chronically, inhalants cause neurological damage that can be irreversible, including leukoencephalopathy (destruction of cerebral white matter), cerebral atrophy, peripheral neuropathy, and permanent cognitive deficits. Liver, kidney, lung, and bone marrow injuries are also documented. Toluene, present in many solvents, is particularly neurotoxic. Chronic users may develop irreversible dementia. These risks make inhalant use particularly dangerous and justify urgent preventive and therapeutic interventions.

Are children and adolescents more vulnerable to the effects of inhalants?

Yes, children and adolescents are particularly vulnerable both to initiating inhalant use and to the adverse effects of inhalants. Vulnerability to initiating use stems from several factors: easy access to household and industrial products, low cost, lack of risk perception, natural curiosity of this age group, and peer influence. Neurologically, the developing brain is more susceptible to damage caused by neurotoxins, and exposure during critical periods of brain maturation can result in lasting cognitive and behavioral impairments. Adolescents may also have reduced capacity to assess risks and control impulses due to immaturity of the prefrontal cortex. Socially, adolescents who use inhalants often face multiple vulnerabilities, including poverty, neglect, trauma, school problems, and lack of family support. Early intervention is crucial, as inhalant use in adolescence is associated with a higher risk of progression to use of other substances and development of severe dependence disorders in adulthood.

Is complete recovery possible after chronic inhalant use?

The possibility of complete recovery depends on multiple factors, including duration and intensity of use, specific type of inhalant, age of the user, extent of damage already caused, and access to adequate treatment. In cases of brief or moderate use, especially if use is discontinued early, complete or near-complete recovery is possible. Many cognitive and behavioral alterations can improve significantly with prolonged abstinence. However, chronic and intense use, particularly of highly neurotoxic substances such as toluene, can cause irreversible brain damage. Neuroimaging in chronic users frequently reveals cerebral atrophy and white matter alterations that may be permanent. Some cognitive deficits, especially in executive functions, memory, and processing speed, may persist even after years of abstinence. Recovery is more favorable in young individuals who cease use early and receive adequate therapeutic support. Cognitive rehabilitation, psychosocial support, and treatment of comorbidities can optimize recovery. The important message is that early intervention maximizes the chances of recovery and minimizes permanent damage.

Conclusion

Disorders due to volatile inhalant use (ICD-11: 6C4B) represent a significant clinical challenge, particularly among young and vulnerable populations. Precise coding of these disorders is fundamental for epidemiological surveillance, health service planning, and ensuring adequate treatment. Health professionals should be alert to signs of inhalant use, perform comprehensive evaluation when there is suspicion, and implement evidence-based interventions. Primary prevention, through education and access restriction, combined with early detection and adequate treatment, are essential to minimize the impact of these disorders on global public health.

External References

This article was developed based on reliable scientific sources:

References verified on 2026-02-03

Disorders Due to Use of Volatile Inhalants

Partager